All participants will be awarded a certificate of completion for self-reporting to other colleges
Duration: 30 minutes
MOH is said to be a biobehavioural disorder, wherein patients believe that they need their headache medication to function. Comorbid psychiatric disorders are also common among these patients. Learn about strategies for patient education and individualising management.
Upon completing this course, participants will be able to:
State why MOH can be considered a biobehavioural disorder
List basic psychological issues that contribute to MOH
Put in place a system for screening patients with MOH for possible psychological comorbidities such as depression and anxiety disorder.
Associate Professor Richard Stark: Co-authored a clinical paper sponsored by Pfizer on the safety of eletriptan. Between 2012 and 2014 received consulting and lecture fees from Allergan and lecture fees from MSD on chronic migraine
Professor Mieke Van Driel: No conflict of interest
Associate Professor Treasure McGuire: No conflict of interest
Dr Brett McFarlane: No conflict of interest
Professor Deborah Turnbull: Received research grants and co-authored papers on hypertension sponsored by pharmaceutical companies, including Pfizer Pty. Ltd., between 1999 and 2006
Dr Lara Mihaljevic: No conflict of interest
Non-faculty: employees of In Vivo Academy involved in producing the content of this course, Yulyana, Tina Garcia, Monica Kurniawan and Lisa Sullivan, declare no conflict of interest.